GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo to match adalimumab
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1759
- Registration Number
- NCT02889796
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1252
- Registration Number
- NCT02886728
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT02885181
- Locations
- 🇺🇸
Center For Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Albuquerque Center For Rheumatology, Albuquerque, New Mexico, United States
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
Phase 2
Active, not recruiting
- Conditions
- HIV-1 Infection
- Interventions
- Drug: B/F/TAF (Adult Strength)Drug: B/F/TAF (Low Dose)Drug: B/F/TAF (TOS)
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 177
- Registration Number
- NCT02881320
- Locations
- 🇺🇸
Children's National Health System, Washington, District of Columbia, United States
🇺🇸Midway Immunology and Research Center, Fort Pierce, Florida, United States
🇺🇸University of Florida Health, Gainesville, Florida, United States
Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- PD Effects of GS-0976 (NDI-010976) on Fractional DNL
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02876796
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 449
- Registration Number
- NCT02873936
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Phase 2
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT02868242
- Locations
- 🇪🇬
National Cancer Institute, Cairo University, Cairo, Egypt
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Completed
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 144
- Registration Number
- NCT02864381
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT02862548
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT02862574
- Locations
- 🇺🇸
Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States
🇺🇸Omega Research Consultants, LLC, DeBary, Florida, United States
🇺🇸Stanford University, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath